Seminars in Oncology
Volume 30, Issue 6 , Pages 730-739 , December 2003

Cardiac effects of adjuvant therapy for early breastcancer

  • Maria Theodoulou

      Affiliations

    • Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Maria Theodoulou, MD, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 USA
    • ,
  • Andrew D Seidman

      Affiliations

    • Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

References 

  1. American Cancer Society: Breast Cancer Facts and Figures, 2001–2002. Atlanta, GA: American Cancer Society; 2002;
  2. Yancik R, Ries LA. Aging and cancer in America. Hematol Oncol Clin North Am. 2000;14: 17–3
  3. Fisher B, Anderson S, Redmond C, et al.  Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995;333:1456–1461
  4. Delouche G, Bachelot F, Premont M, et al.  Conservation treatment of early breast cancer (Long term results and complications). Int J Radiat Oncol Biol Phys. 1987;13:29–34
  5. Schultz-Hector S. Radiation-induced heart disease (Review of experimental data on dose response and pathogenesis). Int J Radiat Biol. 1992;61:149–160
  6. Rutqvist LE, Liedberg A, Hammar N, et al.  Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys. 1998;40:359–363
  7. Cuzick J, Stewart H, Rutqvist L, et al.  Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–453
  8. Kaplan H. Radiotherapy. In:  Kaplan H editors. Hodgkin’s Disease. Cambridge, MA: Harvard University Press; 1972;p. 336–391
  9. Stewart J, Cohen K, Fajardo L, et al.  Radiation-induced heart disease (A study of twenty-five patients). Radiology. 1967;89:302–310
  10. Lobo R. Hormones, hormone replacement therapy and heart disease. In:  Douglas P editors. Cardiovascular Health and Disease in Women. Philadelphia, PA: Saunders; 1993;p. 153–174
  11. Ali M, Ewer M. Cardiovascular problems in the patient with cancer (Radiation-related heart disease). Prim Care Center. 1989;9:11–15
  12. Ewer MS, Benjamin RS. Cardiac complications. In:  Holland JF,  Frei E,  Bast RC, et al. editor. Cancer Medicine. (ed 5). Hamilton, Canada: Decker; 2000;p. 2324–2339
  13. Ferri G, Dusi U. Radiazoni ionizzant e cuore (Part I). Quad Radiol. 1965;30:1007–1032
  14. Amromin G, Gildenhorn H, Solomon R, et al.  The synergism of x-irradiation and cholesterol-fat feeding on the development of coronary artery lesions. J Atherosclerosis Res. 1964;4:325–334
  15. Stewart R, Fajardo L, Gillette S, et al.  Radiation injury to the heart. Int J Radiat Oncol Biol Phys. 1995;31:1205–1211
  16. Early Breast Cancer Trialists’ Collaborative Group . Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer (An overview of the randomised trials). Lancet. 2000;355:1757–1770
  17. Paszat L, Mackillop W, Groome P, et al.  Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the Surveillance, Epidemiology, and End-Results cancer registries. J Clin Oncol. 1998;16:2625–2631
  18. Nixon AJ, Manola J, Gelman R, et al.  No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol. 1998;16:1374–1379
  19. Vallis KA, Pintilie M, Chong N, et al.  Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol. 2002;20:1036–1042
  20. Shapiro CL, Hardenbergh PH, Gelman R, et al.  Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol. 1998;16:3493–3501
  21. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al.  Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001;19:2746–2753
  22. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive lymph nodes. Ten-year results. JAMA. 1995;273:542–547
  23. Citron ML, Berry DA, Cirrincione C, et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer (First report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741). J Clin Oncol. 2003;21:1431–1439
  24. Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites (Alterations produced by doxorubicin). J Clin Invest. 1980;65:128–135
  25. Keefe D. Anthracycline-induced cardiomyopathy. Semin Oncol. 2001;28(suppl 12):2–7
  26. Fumoleau P, Kerbrat P, Romestaing P, et al.  Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients (10-year follow-up results of the French adjuvant study 01 trial). J Clin Oncol. 2003;21:298–305
  27. Benjamin R, Chawla S, Ewer M, et al.  Adriamycin cardiac toxicity—An assessment of approaches to cardiac monitoring and cardioprotection. In:  Hacker M,  Lazo J,  Tritton T editor. Organ Directed Toxicities of Anticancer Drugs. Boston, MA: Martinus Nijhoff; 1988;p. 44–55
  28. The Cancer and Leukemia Group B Budman DR, Berry DA, Cirrincione CT, et al.  Dose and dose intensity as determinants of the outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998;90:1205
  29. Henderson IC, Berry D, Demetri G, et al.  Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol. 1998;17:101a; (abstr 390A)
  30. Von Hoff DD, Layard MW, Basa P, et al.  Risk Factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  31. Aviles A, Arevila N, Diaz Maqueo JC, et al.  Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin’s disease in adults. Leuk Lymphoma. 1993;11:275–279
  32. Lefrak EA, Pitha J, Rosenheim S, et al.  A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer. 1973;32:302–314
  33. Zambetti M, Moliterni A, Materazzo C, et al.  Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol. 2001;19:37–43
  34. Bristow M, Thompson P, Martin R, et al.  Early anthracycline cardiotoxicity. Am J Med. 1978;65:823–832
  35. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity (current practice and prospects of prophylaxis). Eur J Heart Failure. 2002;4:235–242
  36. Frishman WH, Sung HM, Yee HC, et al.  Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cancer. 1997;21:301–360
  37. Goethals I, DeWinter O, DeBondt P, et al.  The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage. Ann Oncol. 2002;13:1331–1339
  38. Steinherz LJ, Steinherz PG, Tan C, et al.  Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672–1677
  39. Singhal P, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905
  40. Jensen BV, Skovsggard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity (A prospective, blinded, long-term observational study of outcome in 120 patients). Ann Oncol. 2002;13:699–709
  41. Lee BH, Goodenday LS, Muswick GJ, et al.  Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987;9:184–188
  42. Mortensen SA, Olsen HS, Baandrup U. Chronic anthracycline cardiotoxicity (Haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease). Br Heart J. 1986;55:274–282
  43. Manson JW, Bristow MR, Billingham ME, et al.  Invasive and noninvasive methods of assessing Adriamycin cardiotoxic effects in man (Superiority of histopathologic assessment using endomyocardial biopsy). Cancer Treat Rep. 1978;68:857–864
  44. Ewer M, Carrasco C, Mackay B, et al.  Cardiac biopsy procedures at a cancer center. Proc Am Soc Clin Oncol. 1991;10:336; (abstr)
  45. Cardinale D, Sandri MT, Martinoni A, et al.  Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710–715
  46. Bernardini N, Agen C, Favilla S, et al.  Doxorubicin cardiotoxicity is associated with alterations of plasma levels of atrial natriuretic factor. J Endocrinol Invest. 1992;15:79–84
  47. Cobleigh MA, Vogel CL, Tripathy D, et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  48. Vogel CL, Cobleigh MA, Tripathy D, et al.  Efficacy and safety of trastuzumab as a single agent in the first-line treatment of HER2 overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  49. Slamon DJ, Leyland-Jones B, Shak S, et al.  Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer (A phase III, multinational, randomized controlled trial). N Engl J Med. 2001;344:783–792
  50. Norton L, Slamon D, Leyland-Jones B, et al.  Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol. 1999;18:127a; (abstr 483)
  51. Seidman A, Hudis C, Pierri MK, et al.  Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  52. Gelmon K, Mackey J, Verma S, et al.  Efficacy and safety of Herceptin in women with HER2-positive metastatic breast cancer who have progressed on a prior Herceptin-containing regimen. Breast Cancer Res Treat. 2002;76(suppl):S113; abstr 440
  53. Keefe D. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592–1600
  54. Dieras V, Fumoleau P, Lotz JP, et al.  Previous cumulative anthracycline dose is the main determinant of LVEF decrease in breast cancer patients treated with trastuzumab (Herceptin) (Results of a French compassionate use program). Breast Cancer Res Treat. 2002;76(suppl):S110; abstr 425
  55. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the treatment of metastatic breast cancer. Anticancer therapy versus cardiotoxicity. Circulation. 2000;102:272–274
  56. Legha SS, Benjamin RS, Mackay B, et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–139
  57. Torti FM, Bristow MR, Howes AE, et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med. 1983;99:745–749
  58. Weiss AJ, Metter GE, Fletcher WS, et al.  Studies on Adriamycin using weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep. 1976;60:813–822
  59. Weiss AJ, Manthel RW. Experience with the use of Adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer. 1997;40:2046–2052
  60. Chlebowski RT, Paroly WS, Pugh RP, et al.  Adriamycin given as a weekly schedule without a loading course (clinically effective with reduced incidence of cardiotoxicity). Cancer Treat Rep. 1980;64:47–51
  61. Niemann B, Mross K, Drevs J, et al.  The pharmacokinetic profile of liposome-encapsulated doxorubicin (TLC D-99; Myocet). Proc Am Soc Clin Oncol. 2001;20:117a; (abstr 463)
  62. Harris L, Batist G, Belt R, et al.  Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer. 2002;94:25–36
  63. Batist G, Ramakrishnan G, Rao CS, et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–1454 19
  64. Wigler N, Inbar M, O’Brien M, et al.  Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol. 2002;21:45a; (abstr 177)
  65. Theodoulou M, Campos S, Batist G, et al.  TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): Final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol. 2002;21:55a; (abstr 216)
  66. Speyer JL, Green MD, Kramer E, et al.  Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med. 1988;319:745–752
  67. Speyer JL, Green MD, Seleniuch-Jacquotte A, et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117–127
  68. Swain SM, Whaley FS, Gerber MC, et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–1332

PII: S0093-7754(03)00474-3

doi: 10.1053/j.seminoncol.2003.08.024

Seminars in Oncology
Volume 30, Issue 6 , Pages 730-739 , December 2003

Article Tools

* Image Usage & Resolution